A Forward Look into The Year Ahead - Research Report on Warner Chilcott Plc., Endo Health Solutions Inc., The Western Union Company, Euronet Worldwide, Inc. and The Procter & Gamble Company
* Reuters is not responsible for the content in this press release.
For best results when printing this announcement, please click on the link below: http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130312:nPn3116760 NEW YORK, March 12, 2013 /PRNewswire/ -- Today, Investors Alliance announced new research reports highlighting Warner Chilcott Plc. (NASDAQ: WCRX), Endo Health Solutions Inc. (NASDAQ: ENDP), The Western Union Company (NYSE: WU), Euronet Worldwide, Inc. (NASDAQ: EEFT) and The Procter & Gamble Company (NYSE: PG). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Warner Chilcott Plc. Research Report After separating from Warner-Lambert in 1996, Warner Chilcott has evolved to become a fully integrated pharmaceutical company with a broad portfolio of leading branded products. However, Wall Street has not been kind to Warner Chilcott in the past year. It had put itself on sale early in 2012, much to investors' delight, but dropped the sale in August. To make matters more difficult, Warner Chilcott's acne treatment drug Doryx is facing generic competition, while Enablex and oral contraceptive Loestrin could both lose their patents by 2015. Nevertheless, Warner Chilcott CFO Paul Herenden comments that the company still has strong strategies for its key franchises. Herendeen asserted that the company is working on improved versions of its existing products and are developing new products such as a Phase 2 product for rosacea and acne, and a Phase 3 treatment for erectile dysfunction. The Full Research Report on Warner Chilcott Plc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/4c53_WCRX] -- Endo Health Solutions Inc. Research Report The patents on Lidoderm patch and Opana ER tablets are due to expire. Lidoderm had sales of $825 million in 2011 and this accounted for 30 percent of the company's revenues. Furthermore, with more deaths arising from painkiller overdose, regulators have been looking more closely on how painkiller manufacturers have been handling their products. The company is setting aside $194 million to cover possible penalties because of a federal investigation into how the company promoted and sold its Lidoderm patch painkilling drug. The Full Research Report on Endo Health Solutions Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/49e0_ENDP] -- The Western Union Company Research Report As the largest global money movement and payment services company, Western Union gets its revenues from charging fees to transfer money all over the world. The company's large size, solid balance sheet, and sustainable pricing power give it a strong competitive advantage over its rivals. This advantage allows Western Union to match competitors' pricing pressures, and prevent new businesses from forming. Western Union is one of the best examples of companies today with wide economic moats that are trading at discounts to their intrinsic values. In an attractive industry, the company's dominant market share allows significant cost and network advantage. It also has operating margins about twice the size of its competitors. Trading at a substantial discount provides the company strong protection against downside risk, and provides a good chance at earning high returns. As the industry consolidates, Western Union has opportunity to grow through both increased market share and expansion into new markets. The company recently ventured into prepaid cards, providing significant growth opportunities playing to its strength of wide distribution. Despite its stock losing about a quarter of its value in 2012, Western Union offered a good 3.70 percent dividend yield. The company also approved a new share repurchase program of $550 million. These initiatives can help strengthen investors' confidence in the stock. Shares of Western Union traded up 3.40 percent on Monday, hitting $13.99. In the previous quarter, the company has reported 45 cents EPS, meeting analysts' expectations. Analysts have issued a buy rating with a $12 to $19 price target. Continuing to build upon its global agent network, it recently announced the expansion of its Direct-to-Bank service to include China and Canada. Q1 2013 results will be released on April 22, 2013. The Full Research Report on The Western Union Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/3b71_WU] -- Euronet Worldwide, Inc. Research Report Euronet focuses on expanding its global network. The company has recently announced the acquisition of Pure Commerce, an Australia-based company offering cloud-based financial and payment solutions. The acquisition would allow Euronet to expand its services and operating markets. The company expects the acquisition to contribute approximately three to four cents to its annual cash EPS in 2013. On February 15, 2013 it will release its Q4 2012 earnings results. With migration from developing to developed countries increasing, remittances are becoming more relevant for all major developing economies in the world. The Full Research Euronet Worldwide, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/3c52_EEFT] -- The Procter & Gamble Company Research Report P&G, the world's largest consumer goods producer, recently reported impressive results for the last three months of 2012, or Q2 2013. The company earned $4.1 billion, up from $1.7 billion earnings during the same quarter in the previous fiscal year. The impressive results are driven by the company's cost-cutting efforts as well as the introduction of new products, including Tide Pods and a new version of the Pantene shampoo. Gaining 1.8 percent in 2012, P&G stands a better chance of performing better in 2013 than its rivals, including Colgate-Palmolive. Due to strategic pricing, the company's sales are increasing. In the long term, it is aiming to increase sales volume while maintaining higher prices. P&G owns some of the best brands in the world that are known for trust and quality, allowing it to charge a premium for its products. Looking ahead, P&G expects to experience stable growth in 2013. The company repurchased $1.4 billion in stock in the latest quarter, totaling of $4 billion worth of repurchases since July 2012. P&G expects to repurchase $6 billion by June. Q3 2013 earnings of P&G are tentatively scheduled to be released on April 24, 2013. The Full Research Report on The Procter & Gamble Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/f3e0_PG] -- Consider Investors Alliance Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks. Contact: Patricia Byers Email: firstname.lastname@example.org Main: +1-(408)-745-7826 SOURCE Investors-Alliance
- Six people injured when camera catches fire at 30 Rockefeller Plaza
- Israel holds off on escalating Gaza barrage; West wants truce |
- Israel holds off on escalating Gaza barrage; West wants truce |
- Russia warns Ukraine after shell crosses border |
- Exclusive: YouTube weighs funding efforts to boost premium content - sources